Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- Status
- SUSPENDED
- Phase
- PHASE2
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
- Status
- TERMINATED
- Phase
- PHASE2
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3